Novo Nordisk A/S holds the cleaner structural position, with growth as the main driver and stability adding further support. Gilead Sciences still has the edge on stability, which keeps the comparison from looking entirely one-sided. The market setup is currently leaning toward Gilead Sciences, which does not confirm the structural lead. That leaves a split case: the structural lead stays with Novo Nordisk A/S, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (GILD: Nasdaq 100, NOVO-B.CO: STOXX 600).
The lead is spread across growth and profitability, rather than sitting in one isolated gap. The overall score gap is 8 points in favour of Novo Nordisk A/S.
Both operate in: Drug Manufacturers - General
This comparison is based on industry proximity, not on functional trajectory similarity. GILD and NOVO-B.CO share the same industry classification.
For a similarity-based comparison, see how Gilead Sciences and Novo Nordisk A/S each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Score differences across key dimensions.
Left means cheaper relative valuation. Higher means stronger structure.
The setup remains mixed because the stronger profile and the more supportive price setup do not sit on the same side.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Where GILD and NOVO-B.CO each sit in their own 5-year price and valuation history.
Describes historical entry positioning only. Descriptive — not investment advice.
The current lead is backed by a stronger multi-year growth trajectory.
Stability still tilts materially toward Gilead Sciences, Inc., which stops the result from looking dominant across the whole profile.
Growth settles the comparison, while pricing and stability keep the broader setup from looking fully aligned.
Break down the GILD vs NOVO-B.CO comparison across all dimensions with the full interactive tool.
Explore how GILD and NOVO-B.CO each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.